Source comparison
Mechanism of Action — IGF-1 LR3 vs Ipamorelin
IGF-1 LR3 bypasses the GH-IGF-1 axis entirely. Native IGF-1 binds tightly to six IGF-binding proteins (IGFBPs) in serum, which sequester the hormone and limit tissue availability. The R3 modification. Substituting glutamic acid with arginine at position 3. Red
This comparison does not assign a generated winner or score.
- IGF-1 LR3 bypasses the GH-IGF-1 axis entirely. Native IGF-1 binds tightly to six IGF-binding proteins (IGFBPs) in serum, which sequester the hormone and limit tissue availability. The R3 modification. Substituting glutamic acid with arginine at position 3. Reduces IGFBP affinity by approximately 85%, allowing the peptide to circulate freely and bind IGF-1 receptors directly. Once bound, it activates PI3K/Akt and MAPK/ERK pathways that drive protein synthesis, glycogen storage, and satellite cell proliferation. Half-life extends to 20–30 hours due to reduced clearance, meaning single daily dosing maintains therapeutic plasma concentrations. Research published in Endocrinology demonstrated that IGF-1 LR3 administration produces muscle hypertrophy in hypophysectomized rats. Animals with no pituitary function. Confirming the GH-independent mechanism.
- Ipamorelin stimulates GH release through selective GHSR1a agonism. Ghrelin receptors exist in high density on somatotroph cells in the anterior pituitary, and Ipamorelin binds with nanomolar affinity (EC50 of 2.3 nM) without cross-reactivity at other peptide receptors. This selectivity matters: earlier GHRPs like GHRP-6 activate cortisol and prolactin alongside GH, introducing confounding variables. Ipamorelin produces isolated GH pulses that peak 30–60 minutes post-administration and return to baseline within 3–4 hours. The released GH then binds hepatic GH receptors, triggering JAK2/STAT5 signaling that upregulates IGF-1 gene transcription. Serum IGF-1 rises gradually over 8–12 hours. This is systemic IGF-1, bound to IGFBPs and distributed through normal physiological channels.